Tazemetostat
Back to searchMolecule Structure
Scientific Name
Tazemetostat
Description of the Drug
Tazemetostat is a methyltransferase inhibitor indicated to treat patients 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12887
http://www.drugbank.ca/drugs/DB12887
Brand Name(s)
Not Available
Company Owner(s)
Epizyme Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Histone-lysine N-methyltransferase EZH2 | SINGLE PROTEIN | INHIBITOR | CHEMBL2189110 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL19325409 | SCHEMBL13276848 | SCHEMBL22210809 |
| Human Metabolome Database | HMDB0304867 | ||
| DrugBank | DB12887 | ||
| PubChem: Thomson Pharma | 152189092 | 163426746 | |
| PubChem | 66558664 | ||
| Nikkaji | J3.394.917K | ||
| BindingDB | 172038 | ||
| DrugCentral | 5380 | ||
| ChemicalBook | CB82655404 | ||
| Guide to Pharmacology | 7011 | ||
| rxnorm | TAZEMETOSTAT | ||
| ZINC | ZINC000100285161 |
